Comparison · NCT00786474-e805af7e
Dalteparin vs Placebo: Major Bleeding
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dalteparin vs Placebo: Major Bleeding. Trial comparisons, record NCT00786474-e805af7e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00786474-e805af7e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0324 | 0.0227 | 0.0461 | wilson | |
| Risk in group 2 | 0.0131 | 0.00749 | 0.0227 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0193 | 0.00562 | 0.0342 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.48 | 1.27 | 4.83 | log | |
| Odds ratio, group 1 over group 2 | 2.53 | 1.28 | 4.99 | log | |
| Number needed to treat, for one more participant with the outcome on Dalteparin than on Placebo | 51.7 | 29.3 | 178 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dalteparin | Dalteparin: Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day | 29 | 895 | OG001 |
| Group 2 | Placebo | Placebo: Normal saline solution, dosage determined by weight, self-administered by patient twice a day | 12 | 918 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Major Bleeding
- Description
- Major bleeding is defined as symptomatic bleeding associated with transfusion of more than two units of packed red blood cells or whole blood, or death
- Time frame
- from subject signing of the consent until completed the study (Day -30 to Day +37)
- Population
- Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data.
Source ClinicalTrials.gov
Trial
- Title
- Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
- NCT number
- NCT00786474
- Phases
- PHASE3
- Conditions
- Arterial Thromboembolic Events, Atrial Fibrillation
- Interventions
- Placebo, Dalteparin
- Lead sponsor
- Duke University
- Results first posted
- 2016-03-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00786474?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00786474-e805af7e